BCL9 Polyclonal antibody

BCL9 Polyclonal Antibody for IF, IHC, WB, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human

Applications

WB, IP, IHC, IF, ELISA

Conjugate

Unconjugated

Cat no : 22947-1-AP

Synonyms

B cell CLL/lymphoma 9, B cell CLL/lymphoma 9 protein, B cell lymphoma 9 protein, BCL9, LGS, Protein legless homolog



Tested Applications

Positive WB detected inJurkat cells
Positive IHC detected inhuman liver cancer tissue, human colon cancer tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
Positive IF detected inHeLa cells

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:500-1:1000
Immunohistochemistry (IHC)IHC : 1:20-1:200
Immunofluorescence (IF)IF : 1:20-1:200
Sample-dependent, check data in validation data gallery

Product Information

The immunogen of 22947-1-AP is BCL9 Fusion Protein expressed in E. coli.

Tested Reactivity human
Cited Reactivity human
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen BCL9 fusion protein Ag19158
Full Name B-cell CLL/lymphoma 9
Calculated molecular weight 1426 aa, 149 kDa
Observed molecular weight 149 kDa
GenBank accession numberBC116451
Gene symbol BCL9
Gene ID (NCBI) 607
Conjugate Unconjugated
Form Liquid
Purification Method Antigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

BCL9 is associated with B-cell acute lymphoblastic leukemia. It may be a target of translocation in B-cell malignancies with abnormalities of 1q21. Its function is unknown. The overexpression of BCL9 may be of pathogenic significance in B-cell malignancies.

Protocols

Product Specific Protocols
WB protocol for BCL9 antibody 22947-1-APDownload protocol
IHC protocol for BCL9 antibody 22947-1-APDownload protocol
IF protocol for BCL9 antibody 22947-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
humanWB,IF,IP

J Biol Chem

USP9X-mediated deubiquitination of B cell CLL/lymphoma 9 potentiates Wnt signaling and promotes breast carcinogenesis.

Authors - Zesen Shang